Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model
Identifieur interne : 004976 ( Main/Exploration ); précédent : 004975; suivant : 004977Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model
Auteurs : Donato A. Di Monte [États-Unis] ; Alison Mccormack [États-Unis, Suède] ; Giselle Petzinger [États-Unis] ; Ann Marie Janson [États-Unis, Suède] ; Maryka Quik [États-Unis] ; William J. Langston [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2000-05.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Animal, Animal model, Animals, Antiparkinson Agents (toxicity), Brain Mapping, Corpus Striatum (drug effects), Corpus Striatum (pathology), Corpus Striatum (physiopathology), Denervation, Dopamine, Dopamine (metabolism), Dyskinesia, Dyskinesia, Drug-Induced (pathology), Dyskinesia, Drug-Induced (physiopathology), Dyskinesias, Levodopa, Levodopa (toxicity), MPTP, Monkey, Monkeys, Neurons (drug effects), Neurons (pathology), Neurons (physiology), Nigrostriatal pathway, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (pathology), Parkinson Disease, Secondary (physiopathology), Parkinson disease, Parkinson's disease, Pathophysiology, Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Saimiri, Substantia Nigra (drug effects), Substantia Nigra (pathology), Substantia Nigra (physiopathology).
- MESH :
- chemical , drug effects : Receptors, Dopamine.
- chemical , metabolism : Dopamine.
- chemical , physiology : Receptors, Dopamine.
- chemical , toxicity : Antiparkinson Agents, Levodopa.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Corpus Striatum, Neurons, Substantia Nigra.
- pathology : Corpus Striatum, Dyskinesia, Drug-Induced, Neurons, Parkinson Disease, Secondary, Substantia Nigra.
- physiology : Neurons.
- physiopathology : Corpus Striatum, Dyskinesia, Drug-Induced, Parkinson Disease, Secondary, Substantia Nigra.
- Animals, Brain Mapping, Denervation, Saimiri.
Abstract
Presynaptic denervation is likely to play an important role in the pathophysiology of dyskinesias that develop after levodopa administration to patients with Parkinson's disease. In this study, the thresholds of nigrostriatal damage necessary for the occurrence of parkinsonism and levodopa‐induced involuntary movements were compared in squirrel monkeys lesioned with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Animals treated with a regimen of MPTP that caused parkinsonism displayed ≥95% striatal dopamine depletion, 90% reduction of striatal dopamine uptake sites, and 70% nigral neuronal loss. Levodopa administration ameliorated the parkinsonian signs of these monkeys but also induced dyskinesias. A separate group of animals was treated with a milder MPTP regimen that caused 60%–70% striatal dopamine depletion, a 50% decrease in dopamine transporter, and 40% loss of dopaminergic nigral neurons. While these monkeys displayed no behavioral signs of parkinsonism, they all became dyskinetic after levodopa administration. The priming effect of levodopa, that is, the recurrence of dyskinesias in animals previously exposed to the drug, was compared in severely versus mildly lesioned monkeys. When severely injured parkinsonian animals underwent a second cycle of levodopa treatment, they immediately and consistently developed involuntary movements. In contrast, the recurrence of dyskinesias in primed monkeys with a partial nigrostriatal lesion required several levodopa administrations and remained relatively sporadic. The data indicate that moderate nigrostriatal damage which does not induce clinical parkinsonism predisposes to levodopa‐induced dyskinesias. Once dyskinesias have been induced, the severity of denervation may enhance the sensitivity to subsequent levodopa exposures.
Url:
DOI: 10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000261
- to stream Istex, to step Curation: 000261
- to stream Istex, to step Checkpoint: 003176
- to stream Main, to step Merge: 007273
- to stream PascalFrancis, to step Corpus: 002C10
- to stream PascalFrancis, to step Curation: 000111
- to stream PascalFrancis, to step Checkpoint: 002B26
- to stream Main, to step Merge: 007518
- to stream PubMed, to step Corpus: 003F83
- to stream PubMed, to step Curation: 003F83
- to stream PubMed, to step Checkpoint: 003E87
- to stream Ncbi, to step Merge: 000268
- to stream Ncbi, to step Curation: 000268
- to stream Ncbi, to step Checkpoint: 000268
- to stream Main, to step Merge: 007030
- to stream Main, to step Curation: 004976
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model</title><author><name sortKey="Di Monte, Donato A" sort="Di Monte, Donato A" uniqKey="Di Monte D" first="Donato A." last="Di Monte">Donato A. Di Monte</name></author><author><name sortKey="Mccormack, Alison" sort="Mccormack, Alison" uniqKey="Mccormack A" first="Alison" last="Mccormack">Alison Mccormack</name></author><author><name sortKey="Petzinger, Giselle" sort="Petzinger, Giselle" uniqKey="Petzinger G" first="Giselle" last="Petzinger">Giselle Petzinger</name></author><author><name sortKey="Janson, Ann Marie" sort="Janson, Ann Marie" uniqKey="Janson A" first="Ann Marie" last="Janson">Ann Marie Janson</name></author><author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name></author><author><name sortKey="Langston, William J" sort="Langston, William J" uniqKey="Langston W" first="William J." last="Langston">William J. Langston</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D13248DD2462D4AB89728A6C73E0B4B654F8743A</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3</idno><idno type="url">https://api.istex.fr/document/D13248DD2462D4AB89728A6C73E0B4B654F8743A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000261</idno><idno type="wicri:Area/Istex/Curation">000261</idno><idno type="wicri:Area/Istex/Checkpoint">003176</idno><idno type="wicri:doubleKey">0885-3185:2000:Di Monte D:relationship:among:nigrostriatal</idno><idno type="wicri:Area/Main/Merge">007273</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:00-0269462</idno><idno type="wicri:Area/PascalFrancis/Corpus">002C10</idno><idno type="wicri:Area/PascalFrancis/Curation">000111</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002B26</idno><idno type="wicri:doubleKey">0885-3185:2000:Di Monte D:relationship:among:nigrostriatal</idno><idno type="wicri:Area/Main/Merge">007518</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:10830409</idno><idno type="wicri:Area/PubMed/Corpus">003F83</idno><idno type="wicri:Area/PubMed/Curation">003F83</idno><idno type="wicri:Area/PubMed/Checkpoint">003E87</idno><idno type="wicri:Area/Ncbi/Merge">000268</idno><idno type="wicri:Area/Ncbi/Curation">000268</idno><idno type="wicri:Area/Ncbi/Checkpoint">000268</idno><idno type="wicri:doubleKey">0885-3185:2000:Di Monte D:relationship:among:nigrostriatal</idno><idno type="wicri:Area/Main/Merge">007030</idno><idno type="wicri:Area/Main/Curation">004976</idno><idno type="wicri:Area/Main/Exploration">004976</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model</title><author><name sortKey="Di Monte, Donato A" sort="Di Monte, Donato A" uniqKey="Di Monte D" first="Donato A." last="Di Monte">Donato A. Di Monte</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Mccormack, Alison" sort="Mccormack, Alison" uniqKey="Mccormack A" first="Alison" last="Mccormack">Alison Mccormack</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Neuroscience, Karolinska Institute, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Petzinger, Giselle" sort="Petzinger, Giselle" uniqKey="Petzinger G" first="Giselle" last="Petzinger">Giselle Petzinger</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Janson, Ann Marie" sort="Janson, Ann Marie" uniqKey="Janson A" first="Ann Marie" last="Janson">Ann Marie Janson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Neuroscience, Karolinska Institute, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Langston, William J" sort="Langston, William J" uniqKey="Langston W" first="William J." last="Langston">William J. Langston</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-05">2000-05</date><biblScope unit="vol">15</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="459">459</biblScope><biblScope unit="page" to="466">466</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D13248DD2462D4AB89728A6C73E0B4B654F8743A</idno><idno type="DOI">10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3</idno><idno type="ArticleID">MDS1006</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Animal</term><term>Animal model</term><term>Animals</term><term>Antiparkinson Agents (toxicity)</term><term>Brain Mapping</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (pathology)</term><term>Corpus Striatum (physiopathology)</term><term>Denervation</term><term>Dopamine</term><term>Dopamine (metabolism)</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (pathology)</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Dyskinesias</term><term>Levodopa</term><term>Levodopa (toxicity)</term><term>MPTP</term><term>Monkey</term><term>Monkeys</term><term>Neurons (drug effects)</term><term>Neurons (pathology)</term><term>Neurons (physiology)</term><term>Nigrostriatal pathway</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (pathology)</term><term>Parkinson Disease, Secondary (physiopathology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Pathophysiology</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (physiology)</term><term>Saimiri</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (pathology)</term><term>Substantia Nigra (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Neurons</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term><term>Dyskinesia, Drug-Induced</term><term>Neurons</term><term>Parkinson Disease, Secondary</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease, Secondary</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Brain Mapping</term><term>Denervation</term><term>Saimiri</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animal</term><term>Dyskinésie</term><term>Enervation</term><term>Modèle animal</term><term>Parkinson maladie</term><term>Physiopathologie</term><term>Singe</term><term>Voie nigrostriatale</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Presynaptic denervation is likely to play an important role in the pathophysiology of dyskinesias that develop after levodopa administration to patients with Parkinson's disease. In this study, the thresholds of nigrostriatal damage necessary for the occurrence of parkinsonism and levodopa‐induced involuntary movements were compared in squirrel monkeys lesioned with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Animals treated with a regimen of MPTP that caused parkinsonism displayed ≥95% striatal dopamine depletion, 90% reduction of striatal dopamine uptake sites, and 70% nigral neuronal loss. Levodopa administration ameliorated the parkinsonian signs of these monkeys but also induced dyskinesias. A separate group of animals was treated with a milder MPTP regimen that caused 60%–70% striatal dopamine depletion, a 50% decrease in dopamine transporter, and 40% loss of dopaminergic nigral neurons. While these monkeys displayed no behavioral signs of parkinsonism, they all became dyskinetic after levodopa administration. The priming effect of levodopa, that is, the recurrence of dyskinesias in animals previously exposed to the drug, was compared in severely versus mildly lesioned monkeys. When severely injured parkinsonian animals underwent a second cycle of levodopa treatment, they immediately and consistently developed involuntary movements. In contrast, the recurrence of dyskinesias in primed monkeys with a partial nigrostriatal lesion required several levodopa administrations and remained relatively sporadic. The data indicate that moderate nigrostriatal damage which does not induce clinical parkinsonism predisposes to levodopa‐induced dyskinesias. Once dyskinesias have been induced, the severity of denervation may enhance the sensitivity to subsequent levodopa exposures.</div></front></TEI><affiliations><list><country><li>Suède</li><li>États-Unis</li></country><region><li>Californie</li><li>Svealand</li></region><settlement><li>Stockholm</li></settlement></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Di Monte, Donato A" sort="Di Monte, Donato A" uniqKey="Di Monte D" first="Donato A." last="Di Monte">Donato A. Di Monte</name></region><name sortKey="Janson, Ann Marie" sort="Janson, Ann Marie" uniqKey="Janson A" first="Ann Marie" last="Janson">Ann Marie Janson</name><name sortKey="Langston, William J" sort="Langston, William J" uniqKey="Langston W" first="William J." last="Langston">William J. Langston</name><name sortKey="Mccormack, Alison" sort="Mccormack, Alison" uniqKey="Mccormack A" first="Alison" last="Mccormack">Alison Mccormack</name><name sortKey="Petzinger, Giselle" sort="Petzinger, Giselle" uniqKey="Petzinger G" first="Giselle" last="Petzinger">Giselle Petzinger</name><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name></country><country name="Suède"><region name="Svealand"><name sortKey="Mccormack, Alison" sort="Mccormack, Alison" uniqKey="Mccormack A" first="Alison" last="Mccormack">Alison Mccormack</name></region><name sortKey="Janson, Ann Marie" sort="Janson, Ann Marie" uniqKey="Janson A" first="Ann Marie" last="Janson">Ann Marie Janson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004976 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004976 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D13248DD2462D4AB89728A6C73E0B4B654F8743A
|texte= Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model
}}
| This area was generated with Dilib version V0.6.23. |  |